Correction: Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy$dstudy protocol of the TRADE-hypo trial

Ähnliche Einträge

• Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial
  von: Bozorgmehr, Farastuk, et al.
  Veröffentlicht: (2020)
• Durvalumab in frail and elderly patients with stage four non-small cell lung cancer: study protocol of the randomized phase II DURATION trial
  von: Kuon, Jonas, et al.
  Veröffentlicht: (2020)
• Protocol of the TREASURE study: Thoracic RadiothErapy with Atezolizumab in Small cell lUng canceR Extensive disease$da randomized, open-label, multicenter phase II trial
  von: Bozorgmehr, Farastuk, et al.
  Veröffentlicht: (2022)
• Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: study protocol of the ABP trial
  von: Christopoulos, Petros, et al.
  Veröffentlicht: (2021)
• Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer : study protocol of the FORCE trial
  von: Bozorgmehr, Farastuk, et al.
  Veröffentlicht: (2019)